Halozyme Therapeutics (HALO) Cost of Revenue (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Cost of Revenue data on file, last reported at $79.2 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $79.2 million, up 63.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $259.6 million (up 44.64% YoY), and the FY2025 annual result was $228.8 million, up 43.51% from the prior year.
• Cost of Revenue rose to $79.2 million in Q1 2026 per HALO's latest filing, from $78.8 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $79.2 million in Q1 2026 and troughed at $15.9 million in Q1 2022.
• A 5-year average of $47.0 million and a median of $47.3 million in 2022 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue soared 154.55% in 2022, then decreased 20.9% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $42.1 million in 2022, then climbed by 24.16% to $52.3 million in 2023, then retreated by 19.59% to $42.1 million in 2024, then jumped by 87.3% to $78.8 million in 2025, then grew by 0.59% to $79.2 million in 2026.
• Business Quant data shows HALO's Cost of Revenue at $79.2 million in Q1 2026, $78.8 million in Q4 2025, and $55.2 million in Q3 2025.